(Q38021692)

27 August 2017

New biomarkers and targets in pancreatic cancer and their application to treatment (English)

1 reference

27 August 2017

0 references

1 reference

Eithne Costello

1

0 references

John P Neoptolemos

object named as

John P Neoptolemos

series ordinal

3

0 references

William Greenhalf

series ordinal

2

object named as

William Greenhalf

1 reference

PubMed ID

22733351

27 August 2017

language of work or name

English

0 references

publication date

26 June 2012

1 reference

Nature Reviews Gastroenterology & Hepatology

27 August 2017

1 reference

27 August 2017

9

1 reference

27 August 2017

8

1 reference

27 August 2017

435-444

1 reference

https://scigraph.springernature.com/pub.10.1038/nrgastro.2012.119

27 August 2017

0 references

cites work

Estimates of cancer incidence and mortality in Europe in 2008.

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

21 January 2018

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Improving outcome for patients with pancreatic cancer through centralization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

A new approach to managing intraductal papillary mucinous pancreatic neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Advanced pancreatic carcinoma: current treatment and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

The patterns and dynamics of genomic instability in metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Distant metastasis occurs late during the genetic evolution of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

EMT and dissemination precede pancreatic tumor formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

The genetic basis for cancer treatment decisions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Identification of serum proteins involved in pancreatic cancer cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Use of archived specimens in evaluation of prognostic and predictive biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

REporting recommendations for tumour MARKer prognostic studies (REMARK)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Diagnosis of pancreatic ductal adenocarcinoma and chronic pancreatitis by measurement of microRNA abundance in blood and tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Multimarker gene analysis of circulating tumor cells in pancreatic cancer patients: a feasibility study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Detection of circulating tumor cells in patients with pancreatic cancer: a preliminary result

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Stromal biology and therapy in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Co-evolution of tumor cells and their microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

The tumor microenvironment and its role in promoting tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Cancer-associated stromal fibroblasts promote pancreatic tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Deploying mouse models of pancreatic cancer for chemoprevention studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

The variable phenotype of the p.A16V mutation of cationic trypsinogen (PRSS1) in pancreatitis families

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Novel approaches to target pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Targeted agents in the treatment of pancreatic cancer: history and lessons learned

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

New treatment options for advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Targeting the cancer initiating cell: the ultimate target for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Development and characterization of gemcitabine-resistant pancreatic tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Notch signalling in solid tumours: a little bit of everything but not all the time

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Targeting Notch signaling in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Cancer. Breaching the cancer fortress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

PARP inhibition: PARP1 and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Expression of glial cell line-derived neurotrophic factor family members and their receptors in pancreatic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

New approaches to the treatment of pancreatic cancer: from tumor-directed therapy to immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Understanding metastasis in pancreatic cancer: a call for new clinical approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

The role of stroma in pancreatic cancer: diagnostic and therapeutic implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Enhancing the translation of cancer biomarkers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

microRNAs as markers of survival and chemoresistance in pancreatic ductal adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Molecular detection of circulating cancer cells during surgery in patients with biliary-pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk groups

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Cancer stem cells: an evolving concept

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

c-Met is a marker of pancreatic cancer stem cells and therapeutic target

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

The hedgehog pathway and pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

BRCA2 germline mutations in familial pancreatic carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Familial pancreatic cancer--current knowledge

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.119

Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer

31 March 2020

1 reference

12 December 2020

HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients

1 reference

12 December 2020

K-ras mutations in pancreatic ductal proliferative lesions

1 reference

12 December 2020

Targeting notch to eradicate pancreatic cancer stem cells for cancer therapy.

1 reference

12 December 2020

Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism

1 reference

12 December 2020

Biology and management of pancreatic cancer

1 reference

12 December 2020

10.1038/NRGASTRO.2012.119

Identifiers

DOI

1 reference

27 August 2017

1 reference

PubMed ID

22733351